Research programme: N-methyl-D-aspartate receptor antagonists and associated analogues - PsyBio Therapeutics
Alternative Names: NMDA receptor antagonists and associated analouges - PsyBio TherapeuticsLatest Information Update: 20 Dec 2022
At a glance
- Originator PsyBio Therapeutics
- Class Antipsychotics
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Neurological disorders; Psychotic disorders; Traumatic brain injuries
Most Recent Events
- 06 Dec 2022 PsyBio Therapeutics files four U.S. Patent Cooperation Treaty (PCT) patent applications related to advancements concerning production methodology, host strains and processes of production .
- 04 Aug 2021 PsyBio Therapeutics files for patent protection with US PTO for NMDA receptor antagonist in USA
- 04 Aug 2021 Early research in Neurological disorders in USA (unspecified route)